Molecular Diagnostics in Clinical Oncology
9 ESCO credits
29.11.2013 - 30.11.2013
Viareggio, Italy
COURSES AND SEMINARS
Description
Chairs: M.S. Aapro, CH - J. Gligorov, FR
The development of specific treatments, with an endocrine and now many other “targets” is revolutionizing cancer treatment. There is a clear need to define the disease of the patient more precisely.
This event will try to find answers to questions such as which parameters are of importance for the efficacy of the treatment, or what can be asked from new methods, what do they bring today and what will they bring tomorrow.
LEARNING OBJECTIVES
• Learn about genomics research and its impact on cancer prognosis and therapy response (prediction)
• Learn how to apply clinical genomics in cancer patients
.
General information
ORGANISING SECRETARIAT
European School of Oncology
Via Turati, 29
20121 Milan, Italy
Programme and Organisation
Roberta Ventura - rventura@eso.net - Tel : +39 02 85464532
Applications
Elena Fiore - efiore@eso.net - Tel: +39 02 85464529
CME ACCREDITATION
The Accreditation Council of Oncology in Europe (ACOE) and the European Accreditation Council for Continuing Medical Education (EACCME) have acknowledged the quality of the scientific programme and its educational value. The Molecular Diagnostics in Clinical Oncology course has been assigned 9 European Continuing Medical Education Credits (ECMEC).
Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.
OFFICIAL LANGUAGE
The official language of the course will be English. No simultaneous translation will be provided.
BADGE
The badge is the only official evidence of registration and should be worn at all times during the course. Loss of badge means loss of registration.
INSURANCE
The organisers bear no responsability for untoward events in relation with the participation in the Seminar. Participants are advised to take out their own personal and travel insurance coverage.
TRAVEL GRANTS
A limited number of travel grants will be available. Requests for support should be submitted together with the application form by the application deadline.
Travel grants in the following amounts will be refunded to successful applicants by bank transfer after the course:
EUR 150 for participants coming from Italy; EUR 250 for participants coming from Southern and Western Europe; EUR 350 for participants coming from Northern Europe; EUR 400 for participants coming from other regions.**
**Please refer to the UN geographical region and composition: http://unstats.un.org/unsd/methods/m49/m49regin.htm#europe
SHARING PROGRESS IN CANCER CARE (SPCC)
Sharing Progress in Cancer Care programme (SPCC) is a pioneering partnership between the European School of Oncology (ESO) and some of the world’s leading pharmaceutical companies.
This course is organized through an unrestricted grant provided by Genomic Health and Novartis Oncology, sustaining members of the SPCC programme.
.
Faculty list
FACULTY
M.S. Aapro, IMO Clinique de Genolier, CH
S. Al-Batran, Krankenhaus Nordwest, Frankfurt, DE
F. Cappuzzo, Istituto Toscano Tumori, Livorno, IT
C. Cremolini, Azienda Ospedaliero-Universitaria Pisana, Pisa, IT
O. Cussenot, Hopitaux Universitaires Paris Est, Paris, FR
M.V. Dieci, Istituto Oncologico Veneto, Padua, IT
E. Felip, Vall d'Hebron University Hospital, Barcelona, ES
J. Fitzpatrick, Irish Cancer Society, Dublin, IE
L. Fumagalli, European Institute of Oncology, Milan, IT
J. Gligorov, Hopitaux Universitaires Paris Est Tenon, Paris, FR
L. Lacroix, Institut Gustave Roussy, Villejuif, FR
M. Lawler, Queen's University Belfast, UK
R. Pirker, Medical University of Vienna, AT
G. Pruneri, European Institute of Oncology, Milan, IT
J. Robert, Institut Bergonié, Bordeaux, FR
D. Rossi, Amedeo Avogadro University of Eastern Piedmont, Novara, IT
R. Rouzier, Insitut Curie, Paris, FR
H. Rugo, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US
D. Schrijvers, Ziekenhuisnetwerk Antwerpen-Middelheim, Antwerp, BE
Programme
29 November
09:00 | Introduction |
09:15 | Personalized cancer medicine: are we there yet? |
| 09:35 | Genomics: An essential aspect for hemato-oncologists |
09:55 | Discussion |
| WHERE DO WE STAND ON LUNG CANCER? |
10:10 | EGFR and lung cancer: How to test and how to use for clinical decision |
10:30 | Lung cancer as a model for the development of personalized medicine |
10:50 | Future developments in medical lung cancer therapy |
11:10 | Discussion |
11:20 | Coffee break |
WHERE DO WE STAND ON COLORECTAL CANCER? | |
11:30 | About k-ras, b-raf and beyond as predictive markers in mCRC |
12:00 | How does the clinician use these data to best treat colon cancer |
| 12:30 | Discussion . |
12:45 | Lunch |
WHERE DO WE STAND ON PROSTATE CANCER? | |
14:30 | Genomic tools in prostate cancer |
15:00 | Biomarkers in prostate cancer |
15:30 | Today's choices, will these new tools change clinical practice? |
| 15:50 | Discussion |
16:00 | Coffee break |
WHERE DO WE STAND ON BREAST CANCER (Part 1)? | |
16:20 | Triple-negative disease: no, not so simple! Can have an excellent prognosis… |
16:40 | (Neo)-adjuvant therapy of breast cancer in specific populations: Which ones? Using which pathology tools to define these populations? |
17:00 | Do genomic tools impact daily practice in breast cancer treatment? |
17:20 | Discussion |
17:30 | End daily programme |
20:00 | Dinner |
30 November
| PHARMACOGENOMICS |
09:00 | A key for proper treatment |
09:20 | Discussion |
WHERE DO WE STAND ON BREAST CANCER (Part 2)? | |
09:30 | Endocrine-resistance: Tools to predict activity of new drugs? |
09:50 | HER-2 biology and overcoming resistance: Recent data |
10:10 | Genomic evaluation of breast cancer: What are the data? |
10:30 | Coffee break |
11:00 | Triple-negative disease relapses after adjuvant chemo: What do you do? Which research is going on? |
11:20 | Next generation sequencing genomic signatures L. Lacroix, FR |
11:40 | Discussion |
| 12:00 | Lunch |